| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 159 | 2020 |
| PD-L1 expression heterogeneity in non–small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections E Munari, G Zamboni, G Lunardi, L Marchionni, M Marconi, M Sommaggio, ... Journal of Thoracic Oncology 13 (8), 1113-1120, 2018 | 159 | 2018 |
| Neuroendocrine carcinoma of the breast: current evidence and future perspectives A Inno, G Bogina, M Turazza, L Bortesi, S Duranti, A Massocco, ... The Oncologist 21 (1), 28-32, 2016 | 137 | 2016 |
| Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy S Gori, A Inno, L Belluomini, P Bocus, Z Bisoffi, A Russo, G Arcaro Critical Reviews in Oncology/Hematology 143, 139-147, 2019 | 136 | 2019 |
| Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? A Inno, M Di Salvatore, T Cenci, M Martini, A Orlandi, A Strippoli, ... Clinical colorectal cancer 10 (4), 325-332, 2011 | 110 | 2011 |
| Contribution of KRAS mutations and c. 2369C> T (p. T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA M Del Re, M Tiseo, P Bordi, A D'Incecco, A Camerini, I Petrini, M Lucchesi, ... Oncotarget 8 (8), 13611, 2017 | 95 | 2017 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 94 | 2021 |
| Cardiotoxicity of aromatase inhibitors in breast cancer patients J Foglietta, A Inno, F de Iuliis, V Sini, S Duranti, M Turazza, L Tarantini, ... Clinical breast cancer 17 (1), 11-17, 2017 | 78 | 2017 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 75 | 2020 |
| Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity A Inno, G Metro, P Bironzo, AM Grimaldi, E Grego, V Di Nunno, V Picasso, ... Tumori Journal 103 (5), 405-421, 2017 | 66 | 2017 |
| Role of cMET in the development and progression of colorectal cancer JCS Pérez-Vargas, P Biondani, C Maggi, M Gariboldi, A Gloghini, A Inno, ... International journal of molecular sciences 14 (9), 18056-18077, 2013 | 63 | 2013 |
| Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ... Clinical lung cancer 21 (6), 498-508. e2, 2020 | 60 | 2020 |
| Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world … L Cantini, G Mentrasti, GL Russo, D Signorelli, G Pasello, E Rijavec, ... ESMO open 7 (2), 100406, 2022 | 48 | 2022 |
| A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation MA Calegari, A Inno, S Monterisi, A Orlandi, D Santini, M Basso, ... British Journal of Cancer 116 (10), 1279-1286, 2017 | 48 | 2017 |
| Role of MGMT as biomarker in colorectal cancer A Inno, G Fanetti, M Di Bartolomeo, S Gori, C Maggi, M Cirillo, R Iacovelli, ... World Journal of Clinical Cases: WJCC 2 (12), 835, 2014 | 42 | 2014 |
| Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis F Petrelli, A De Stefani, F Trevisan, C Parati, A Inno, B Merelli, M Ghidini, ... Critical reviews in oncology/hematology 144, 102830, 2019 | 40 | 2019 |
| Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study A Cortellini, A De Giglio, K Cannita, DL Cortinovis, R Cornelissen, ... Thoracic Cancer 12 (6), 880-889, 2021 | 38 | 2021 |
| One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis A Inno, S Barni, A Ghidini, A Zaniboni, F Petrelli Breast cancer research and treatment 173, 247-254, 2019 | 36 | 2019 |
| Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma MW Löffler, S Gori, F Izzo, A Mayer-Mokler, PA Ascierto, A Königsrainer, ... Clinical Cancer Research 28 (12), 2555-2566, 2022 | 32 | 2022 |
| Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis A Inno, G Roviello, A Ghidini, A Luciani, M Catalano, S Gori, F Petrelli Critical Reviews in Oncology/Hematology 165, 103434, 2021 | 31 | 2021 |
Carlo Antonio BaroneProfessore Emerito, Università Cattolica Sacro CuoreVerified email at unicatt.it
